Related Experiment Videos
[The effect of a reduction in plasma cholesterol on the evolution of coronary disease]
F Fernández-Avilés1, E García-Morán
1Servicio de Cardiología, Hospital Universitario de Valladolid.
Insights
Lowering high cholesterol levels significantly reduces cardiovascular events and mortality in patients with coronary heart disease. Cholesterol reduction therapy is crucial for secondary prevention, especially after revascularization procedures.
Area of Science:
- Cardiology
- Atherosclerosis Research
Background:
- Elevated serum cholesterol is a primary cause of coronary atherosclerosis, leading to plaque rupture and thrombus formation.
- Cholesterol adversely affects endothelial cell function, contributing to cardiovascular disease progression.
Purpose of the Study:
- To evaluate the impact of cholesterol reduction therapy on secondary prevention in patients with coronary heart disease.
- To emphasize the importance of cholesterol management in patients who have undergone revascularization procedures.
Main Methods:
- Analysis of secondary prevention trials investigating cholesterol reduction therapy.
- Assessment of cardiovascular events, revascularization procedures, and mortality rates.
Main Results:
- Cholesterol reduction therapy shows modest effects on lesion progression but significantly decreases cardiovascular events.
- Therapy reduces rates of coronary surgery, angioplasty, and both coronary and non-coronary heart disease mortality.
- Benefits likely stem from improved plaque stability, reduced vulnerability, and decreased thrombogenicity.
Conclusions:
- Cholesterol lowering is vital for secondary prevention in coronary heart disease patients, reducing adverse events and mortality.
- Special attention to cholesterol management is required for patients with prior revascularization to optimize long-term outcomes and healthcare resource utilization.
Abstract:
Elevated serum cholesterol level has a causal role in the genesis of coronary atherosclerosis and causes plaque activation because it leads to plaque rupture, increases thrombus formation and adversely influences the function of endothelial cells. In patients with evidence of coronary heart disease (angina pectoris, previous myocardial infarction or previous coronary revascularization) the overall effect of cholesterol reduction therapy on the progression of lesions is modest. Nevertheless, the results of secondary prevention trials provide evidence that a reduction in the level of cholesterol leads to a significant decrease in the rate of cardiovascular events, in the rate of new procedures of revascularization by means of coronary surgery or angioplasty, in the coronary-heart-disease-mortality and in the non-coronary-heart-disease mortality. These effects probably mean some benefit on function, vulnerability and thrombogenicity of the plaque. In patients with previous revascularization procedures interest of secondary prevention by means of cholesterol lowering must be special, because in them the probability of long-term success should be optimized for the maximum patient benefit and the best use of health-care resources.